Call Options

8 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$21.87 - $25.59 $457,083 - $534,831
-20,900 Reduced 57.89%
15,200 $387,000
Q1 2024

May 15, 2024

SELL
$21.81 - $25.14 $148,308 - $170,952
-6,800 Reduced 15.85%
36,100 $848,000
Q4 2023

Feb 14, 2024

BUY
$14.29 - $25.95 $577,316 - $1.05 Million
40,400 Added 1616.0%
42,900 $1.08 Million
Q3 2023

Nov 14, 2023

BUY
$14.45 - $20.34 $8,670 - $12,204
600 Added 31.58%
2,500 $36,000
Q2 2023

Aug 14, 2023

SELL
$17.13 - $23.74 $66,807 - $92,586
-3,900 Reduced 67.24%
1,900 $35,000
Q1 2023

May 15, 2023

SELL
$19.34 - $24.11 $42,548 - $53,042
-2,200 Reduced 27.5%
5,800 $130,000
Q4 2022

Feb 14, 2023

SELL
$12.64 - $25.52 $115,024 - $232,232
-9,100 Reduced 53.22%
8,000 $203,000
Q3 2022

Nov 14, 2022

BUY
$12.14 - $18.42 $66,770 - $101,310
5,500 Added 47.41%
17,100 $208,000

Others Institutions Holding OLK

About Olink Holding AB (publ)


  • Ticker OLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 119,098,000
  • Description
  • Olink Holding AB (publ) provides various products and services for the academic, government, biopharmaceutical, biotechnology, and other institutions that focuses on life science research. Its products include Olink Explore for cardiovascular and metabolic, oncology, neurology, or inflammation diseases; Olink Target product line; and Olink Focus...
More about OLK
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.